Page last updated: 2024-12-08

bh 3

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

BH 3: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	135882
SCHEMBL ID	11659316
MeSH ID	M0047971

Synonyms (20)

Synonym
OPREA1_145341 ,
bh 3
4-(1-aminoethyl)-2,6-ditert-butylphenol
AKOS005459312
STK525789
4-(1-aminoethyl)-2,6-di-tert-butylphenol
728-39-2
unii-8yic941e3v
bh-3
2,6-di-tert-butyl-4-(aminomethyl)phenol hydrochloride
4-(1-aminoethyl)-2,6-bis(1,1-dimethylethyl)phenol
alpha-methyl-3,5-di-tert-butyl-4-hydroxybenzylamine
8yic941e3v ,
SCHEMBL11659316
4-hydroxy-3,5-di-tert-butyl-.alpha.-methylbenzylamine
phenol, 4-(1-aminoethyl)-2,6-bis(1,1-dimethylethyl)-
phenol, 4-(1-aminoethyl)-2,6-di-tert-butyl-
1-(3,5-di-t-butyl-4-hydroxyphenyl)ethylamine
DTXSID50993599
Q27271207

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	6 (66.67)	29.6817
2010's	2 (22.22)	24.3611
2020's	1 (11.11)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 44.80

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	44.80 (24.57)
Research Supply Index	2.30 (2.92)
Research Growth Index	4.51 (4.65)
Search Engine Demand Index	63.12 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (44.80)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	9 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
serine Serine: A non-essential amino acid occurring in natural form as the L-isomer. It is synthesized from GLYCINE or THREONINE. It is involved in the biosynthesis of PURINES; PYRIMIDINES; and other amino acids.. serine : An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group.	2.01	1	L-alpha-amino acid; proteinogenic amino acid; serine family amino acid; serine zwitterion; serine	algal metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
kainic acid Kainic Acid: (2S-(2 alpha,3 beta,4 beta))-2-Carboxy-4-(1-methylethenyl)-3-pyrrolidineacetic acid. Ascaricide obtained from the red alga Digenea simplex. It is a potent excitatory amino acid agonist at some types of excitatory amino acid receptors and has been used to discriminate among receptor types. Like many excitatory amino acid agonists it can cause neurotoxicity and has been used experimentally for that purpose.	2.01	1	dicarboxylic acid; L-proline derivative; non-proteinogenic L-alpha-amino acid; pyrrolidinecarboxylic acid	antinematodal drug; excitatory amino acid agonist
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	2.03	1	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
etoposide [no description available]	2.03	1	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
abt-737 [no description available]	2.99	4	aromatic amine; aryl sulfide; biphenyls; C-nitro compound; monochlorobenzenes; N-arylpiperazine; N-sulfonylcarboxamide; secondary amino compound; tertiary amino compound	anti-allergic agent; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone: an interleukin-1beta converting enzyme (ICE)-like protease inhibitor	2.04	1
nitrophenols Nitrophenols: PHENOLS carrying nitro group substituents.	2.99	4

Condition	Relationship Strength	Studies
Infections, Picornaviridae [description not available]	2.31	1
Poultry Diseases Diseases of birds which are raised as a source of meat or eggs for human consumption and are usually found in barnyards, hatcheries, etc. The concept is differentiated from BIRD DISEASES which is for diseases of birds not considered poultry and usually found in zoos, parks, and the wild.	2.31	1
Hepatitis, Viral, Animal INFLAMMATION of the LIVER in animals due to viral infection.	2.31	1
Autoimmune Lymphoproliferative Syndrome Rare congenital lymphoid disorder due to mutations in certain Fas-Fas ligand pathway genes. Known causes include mutations in FAS, TNFSF6, NRAS, CASP8, and CASP10 proteins. Clinical features include LYMPHADENOPATHY; SPLENOMEGALY; and AUTOIMMUNITY.	2.15	1
Bladder Cancer [description not available]	2.13	1
Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER.	2.13	1
Carcinoma, Transitional Cell A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.	2.13	1
Carcinoma, Small Cell Lung [description not available]	2.04	1
Cancer of Lung [description not available]	2.44	2
Lung Neoplasms Tumors or cancer of the LUNG.	2.44	2
Small Cell Lung Carcinoma A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).	2.04	1
Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.	2.05	1
Carcinoma, Non-Small Cell Lung [description not available]	2.03	1
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	2.03	1
Cancer of Stomach [description not available]	2.04	1
Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.	2.04	1
Stomach Neoplasms Tumors or cancer of the STOMACH.	2.04	1

chemdatabank.com